Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics

DelveInsight's "Glioma - Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies, including Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, and others developing drugs in the Glioma pipeline landscape.
DelveInsight's "Glioma - Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type. The report further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Glioma treatment landscape. Learn more about the evolving Glioma pipeline today @ https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Glioma Pipeline Report

*
In March 2026, GT Medical Technologies initiates BRIDGES trial enrollment, testing GammaTile brachytherapy implant post-resection vs. standard radiation in newly diagnosed GBM to improve survival.

*
In March 2026, STELLAR trial reports >45% survival increase (35 months median OS) with eflornithine + lomustine vs. lomustine alone in recurrent grade 3 IDH-mutant astrocytoma.

*
In February 2026, IN8bio Phase I/II data shows repeated gamma-delta T-cell therapy yields 13-month PFS and >17-month OS in newly diagnosed GBM, doubling standard care benchmarks.

*
In January 2026, Multicenter trial demonstrates focused ultrasound blood-brain barrier opening + temozolomide achieves 13.5-month PFS and 31.3-month OS in newly diagnosed GBM.

*
In November 2025, ImmunityBio Phase 2 QUILT-3.078 reports median OS not reached in recurrent GBM with chemo-free ANKTIVA + CAR-NK, bevacizumab, and Optune; reverses lymphopenia.

*
DelveInsight's Glioma Pipeline Insight report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.

*
The leading Glioma companies include Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, and others.

*
Promising Glioma therapies under development include AV-GBM-1, DB 107, MDNA55, Abemaciclib, NMS-03305293, CAN-3110, MB-101, and others.

*
The company with the most advanced Glioma drug candidate is Aivita Biomedical, Inc., with AV-GBM-1 currently in Phase III clinical development.

*
The Glioma pipeline covers all clinical phases as well as inactive and discontinued candidates.

Download for updates and the latest revolution in Glioma care @ Glioma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Glioma Emerging Drugs Profile

AV-GBM-1: Aivita Biomedical, Inc.

AV-GBM-1 is an innovative immunotherapy developed by Aivita Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. AV-GBM-1 is currently in Phase III of its clinical trial for the treatment of Glioma.

DB 107: Denovo BioPharma

Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. DB107 is currently in Phase II of its clinical trial for the treatment of Glioma.

MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is a targeted therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the delivery vehicle for a potent bacterial toxin, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to combat cancer. MDNA55 is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the Pseudomonas exotoxin A. Because the IL-4 receptor is not found in a healthy brain and the exotoxin is only active inside cancer cell cytoplasm, healthy cells remain unaffected. MDNA55 is currently in Phase II of its clinical trial for the treatment of Glioma.

Abemaciclib: Eli Lilly and Company

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) involved in the cell cycle and promotion of cancer cell growth. It selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. Abemaciclib has been investigated in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. It is currently being evaluated in Phase II development to treat patients with Glioblastoma.

NMS-03305293: Nerviano Medical Sciences

NMS-03305293 (NMS-293) is a second-generation PARP inhibitor distinguished by its unique selectivity for PARP1 versus PARP2 enzymes and low DNA trapping activity - features that are potentially linked to lower hematological toxicity and a higher potential for combination with DNA-damaging agents across a wide range of tumors. It also has a superior ability to penetrate the blood-brain barrier, supporting its utilization in CNS tumors and brain metastases. Based on high anti-tumor activity as a single agent in BRCA-mutated preclinical models and demonstrated synergy with chemotherapy, NMS-293 is currently in Phase II clinical development in combination with temozolomide for recurrent glioblastoma.

CAN-3110: Candel Therapeutics

CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is conditional on the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a Phase I investigator-sponsored clinical trial in patients with recurrent high-grade glioma (HGG).

MB-101: Mustang Bio

MB-101 is an IL13R2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. MB-101 is currently in Phase I of its clinical trial for the treatment of Glioma.

For more information on the Glioma Emerging Drugs Profile, download DelveInsight's comprehensive Glioma Pipeline Insight report [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Glioma Pipeline Report Provides

*
Detailed insights about companies developing therapies for Glioma, with aggregate therapies developed by each company.

*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Glioma treatment.

*
Glioma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Glioma drugs under development based on stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Glioma market.

Learn more about Glioma drug opportunities in our comprehensive Glioma pipeline report @ Glioma Unmet Needs [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Glioma Companies and Competitive Landscape

There are 180+ key companies developing therapies for Glioma. These include Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Aveta Biomics, Angiochem, Arog Pharmaceuticals, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others - with Aivita Biomedical, Inc. having its Glioma drug candidate, AV-GBM-1, in the most advanced Phase III stage.

DelveInsight's Glioma pipeline report provides therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Glioma products have been categorized under various Molecule types such as:

*
Oligonucleotide

*
Peptide

*
Small molecule

Discover the latest advancements in Glioma treatment. Stay informed @ Glioma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Scope of the Glioma Pipeline Report

*
Coverage: Global

*
Glioma Companies: Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Aveta Biomics, Angiochem, Arog Pharmaceuticals, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.

*
Glioma Therapies: AV-GBM-1, DB 107, MDNA55, Abemaciclib, NMS-03305293, CAN-3110, MB-101, and others.

*
Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

*
Introduction

*
Executive Summary

*
Glioma: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Glioma - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Glioma Key Companies

*
Glioma Key Products

*
Glioma Unmet Needs

*
Glioma Market Drivers and Barriers

*
Glioma Future Perspectives and Conclusion

*
Glioma Analyst Views

*
Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-pipeline-expands-as-180-pharma-companies-advance-several-novel-therapies-finds-delveinsight-aivita-biomedical-denovo-biopharma-medicenna-therapeutics-eli-lilly-candel-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.